Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Legend Biotech Corp. (LEGN) PT Raised to $86 at RBC Capital
May 14, 2024 6:11 AM EDTRBC Capital analyst Leonid Timashev raised the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $86.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "This morning LEGN reported 1Q24 earnings and we had a chance to catch up with... More



